Back to Browse Journals » Vascular Health and Risk Management » Volume 8

Ezetimibe therapy: mechanism of action and clinical update

Authors Phan BAP, Dayspring TD, Toth PP

Published Date July 2012 Volume 2012:8 Pages 415—427

DOI http://dx.doi.org/10.2147/VHRM.S33664

Received 7 May 2012, Accepted 23 May 2012, Published 3 July 2012

Binh An P Phan,1 Thomas D Dayspring,2 Peter P Toth3

1Division of Cardiology, Loyola University Medical Center, Maywood, IL, USA; 2Foundation for Health Improvement and Technology, Wayne, NJ, USA; 3CGH Medical Center, Sterling, IL, USA

Abstract: The lowering of low-density lipoprotein cholesterol (LDL-C) is the primary target of therapy in the primary and secondary prevention of cardiovascular events. Although statin therapy is the mainstay for LDL-C lowering, a significant percentage of patients prescribed these agents either do not achieve targets with statin therapy alone or have partial or complete intolerance to them. For such patients, the use of adjuvant therapy capable of providing incremental LDL-C reduction is advised. One such agent is ezetimibe, a cholesterol absorption inhibitor that targets uptake at the jejunal enterocyte brush border. Its primary target of action is the cholesterol transport protein Nieman Pick C1 like 1 protein. Ezetimibe is an effective LDL-C lowering agent and is safe and well tolerated. In response to significant controversy surrounding the use and therapeutic effectiveness of this drug, we provide an update on the biochemical mechanism of action for ezetimibe, its safety and efficacy, as well as the results of recent randomized studies that support its use in a variety of clinical scenarios.

Keywords: bile, coronary artery disease, ezetimibe, low-density lipoprotein cholesterol, Nieman pick C1 like 1 protein, statin

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Effects of magnetic cobalt ferrite nanoparticles on biological and artificial lipid membranes

Drašler B, Drobne D, Novak S, Valant J, Boljte S, Otrin L, Rappolt M, Sartori B, Iglič A, Kralj-Iglič V, Šuštar V, Makovec D, Gyergyek S, Hočevar M, Godec M, Zupanc J

International Journal of Nanomedicine 2014, 9:1559-1581

Published Date: 27 March 2014

Monitoring human papillomavirus prevalence in urine samples: a review [Corrigendum]

Enerly E, Olofsson C, Nygård M

Clinical Epidemiology 2013, 5:371-372

Published Date: 18 September 2013

Tat peptide-decorated gelatin-siloxane nanoparticles for delivery of CGRP transgene in treatment of cerebral vasospasm [Corrigendum]

Tian XH, Wang ZG, Meng H, Wang YH, Feng W, Wei F, Huang ZC, Lin XN, Ren L

International Journal of Nanomedicine 2013, 8:2129-2130

Published Date: 13 June 2013

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment

Lukashevich V, Schweizer A, Foley JE, Dickinson S, Groop PH, Kothny W

Vascular Health and Risk Management 2013, 9:21-28

Published Date: 23 January 2013

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]

Tsumura T, Yoshikawa K, Suzumura H, Kimura T, Sasaki S, Kimura I, Takeda R

Clinical Ophthalmology 2013, 7:129-130

Published Date: 16 January 2013

Corrigendum

Basit A, Riaz M, Fawwad A

Vascular Health and Risk Management 2013, 9:1-2

Published Date: 27 December 2012

Comparison of efficacy of long-acting bronchodilators in emphysema dominant and emphysema nondominant chronic obstructive pulmonary disease

Fujimoto K, Kitaguchi Y, Kanda S, Urushihata K, Hanaoka M, Kubo K

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:219-227

Published Date: 1 April 2011

Decreased lung carcinoma cell density on select polymer nanometer surface features for lung replacement therapies

Lijuan Zhang, Young Wook Chun, Thomas J Webster

International Journal of Nanomedicine 2010, 5:269-275

Published Date: 20 April 2010